antineoplastic agents

Summary

Summary: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Top Publications

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
  2. pmc Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
  3. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
  4. ncbi Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
  5. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
  6. ncbi Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
  7. ncbi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Makoto Maemondo
    Miyagi Cancer Center, Miyagi, Japan
    N Engl J Med 362:2380-8. 2010
  8. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
  9. ncbi Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
    Jane E Visvader
    VBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia
    Nat Rev Cancer 8:755-68. 2008
  10. ncbi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007

Detail Information

Publications275 found, 100 shown here

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
    ..Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate...
  2. pmc Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    Paul B Chapman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    N Engl J Med 364:2507-16. 2011
    ..Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation...
  3. ncbi Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    Thomas J Lynch
    Cancer Center, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    N Engl J Med 350:2129-39. 2004
    ..However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown...
  4. ncbi Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    Tony S Mok
    State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
    N Engl J Med 361:947-57. 2009
    ..Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer...
  5. ncbi EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy
    J Guillermo Paez
    Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Science 304:1497-500. 2004
    ..These results suggest that EGFR mutations may predict sensitivity to gefitinib...
  6. ncbi Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Yung Jue Bang
    Seoul National University College of Medicine, Seoul, South Korea
    Lancet 376:687-97. 2010
    ....
  7. ncbi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
    Makoto Maemondo
    Miyagi Cancer Center, Miyagi, Japan
    N Engl J Med 362:2380-8. 2010
    ....
  8. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
    ....
  9. ncbi Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
    Jane E Visvader
    VBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia
    Nat Rev Cancer 8:755-68. 2008
    ..The clinical relevance of CSCs remains a fundamental issue but preliminary findings indicate that specific targeting may be possible...
  10. ncbi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Science 316:1039-43. 2007
    ..Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well...
  11. ncbi Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
    Hannah Farmer
    Cancer Research UK Gene Function and Regulation Group, London, UK
    Nature 434:917-21. 2005
    ..These results illustrate how different pathways cooperate to repair damage, and suggest that the targeted inhibition of particular DNA repair pathways may allow the design of specific and less toxic therapies for cancer...
  12. ncbi Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    Tetsuya Mitsudomi
    Department of Thoracic Surgery, Aichi Cancer Center Hospital, Chikusa ku, Nagoya, Japan
    Lancet Oncol 11:121-8. 2010
    ..However, whether gefitinib is better than standard platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain...
  13. pmc Inhibition of mutated, activated BRAF in metastatic melanoma
    Keith T Flaherty
    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, USA
    N Engl J Med 363:809-19. 2010
    ..The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted therapy for this disease...
  14. ncbi Hypoxia--a key regulatory factor in tumour growth
    Adrian L Harris
    Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Nat Rev Cancer 2:38-47. 2002
    ..Many elements of the hypoxia-response pathway are therefore good candidates for therapeutic targeting...
  15. ncbi Identification of selective inhibitors of cancer stem cells by high-throughput screening
    Piyush B Gupta
    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Cell 138:645-59. 2009
    ..This study demonstrates the ability to identify agents with specific toxicity for epithelial CSCs...
  16. ncbi Targeting PI3K signalling in cancer: opportunities, challenges and limitations
    Jeffrey A Engelman
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02129, USA
    Nat Rev Cancer 9:550-62. 2009
    ..I focus on the advantages and drawbacks of different treatment strategies for targeting this pathway, the cancers that might respond best to these therapies and the challenges and limitations that confront their clinical development...
  17. ncbi Tumour stem cells and drug resistance
    Michael Dean
    Laboratory of Genomic Diversity, National Cancer Institute Frederick, Frederick, Maryland 21702, USA
    Nat Rev Cancer 5:275-84. 2005
    ..Gaining a better insight into the mechanisms of stem-cell resistance to chemotherapy might therefore lead to new therapeutic targets and better anticancer strategies...
  18. ncbi Defining the role of mTOR in cancer
    David A Guertin
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 02141, USA
    Cancer Cell 12:9-22. 2007
    ..We further discuss the use of rapamycin in oncology and conclude with a discussion on the future of mTOR-targeted therapy...
  19. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
    ....
  20. ncbi Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
    Helen E Bryant
    The Institute for Cancer Studies, University of Sheffield, Medical School, Beech Hill Road, Sheffield S10 2RX, UK
    Nature 434:913-7. 2005
    ..The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment...
  21. ncbi Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
    Wendy De Roock
    Centre for Human Genetics, KU Leuven, Leuven, Belgium
    Lancet Oncol 11:753-62. 2010
    ....
  22. ncbi An inhibitor of Bcl-2 family proteins induces regression of solid tumours
    Tilman Oltersdorf
    Idun Pharmaceuticals, 9380 Judicial Drive, San Diego, California 92121, USA
    Nature 435:677-81. 2005
    ....
  23. ncbi Multidrug resistance in cancer: role of ATP-dependent transporters
    Michael M Gottesman
    Laboratory of Cell Biology and Cancer Therapeutics Branch, The Center for Cancer Research, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 2:48-58. 2002
    ..Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy...
  24. ncbi ERBB receptors and cancer: the complexity of targeted inhibitors
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, CH 4058 Basel, Switzerland
    Nat Rev Cancer 5:341-54. 2005
    ..We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response...
  25. ncbi Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    Brian I Rini
    Cleveland Clinic Taussig Cancer Institute, Main Campus, Euclid Avenue, Cleveland, OH 44195, USA
    Lancet 378:1931-9. 2011
    ....
  26. ncbi EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Susumu Kobayashi
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
    N Engl J Med 352:786-92. 2005
    ..Structural modeling and biochemical studies showed that this second mutation led to gefitinib resistance...
  27. ncbi Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
    ....
  28. pmc Everolimus for advanced pancreatic neuroendocrine tumors
    James C Yao
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 364:514-23. 2011
    ..We evaluated the agent in a prospective, randomized, phase 3 study...
  29. ncbi The role of autophagy in cancer development and response to therapy
    Yasuko Kondo
    Department of Neurosurgery, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Cancer 5:726-34. 2005
    ..What is the present state of our knowledge about the role of autophagy in cancer development, and in response to therapy? And how can the autophagic process be manipulated to improve anticancer therapeutics?..
  30. pmc Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    William Pao
    Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    PLoS Med 2:e73. 2005
    ..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance...
  31. ncbi Anticancer activities of histone deacetylase inhibitors
    Jessica E Bolden
    Cancer Immunology Program, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne 3002, Victoria, Australia
    Nat Rev Drug Discov 5:769-84. 2006
    ....
  32. pmc Targeting the phosphoinositide 3-kinase pathway in cancer
    Pixu Liu
    Department of Cancer Biology, Dana Farber Cancer Institute, Pathology, Harvard Medical School, Boston, MA 02115, USA
    Nat Rev Drug Discov 8:627-44. 2009
    ..Here, we highlight recent progress that has been made in our understanding of the PI3K pathway and discuss the potential of and challenges for the development of therapeutic agents that target this pathway in cancer...
  33. pmc Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
    Kenneth P Olive
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 ORE, UK
    Science 324:1457-61. 2009
    ..Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer...
  34. ncbi Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    James A Bonner
    Department of Medicine, University of Alabama, Birmingham, USA
    N Engl J Med 354:567-78. 2006
    ....
  35. ncbi Epidermal growth factor receptor mutations in lung cancer
    Sreenath V Sharma
    Massachusetts General Hospital Cancer Center and Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA
    Nat Rev Cancer 7:169-81. 2007
    ....
  36. ncbi Microtubules as a target for anticancer drugs
    Mary Ann Jordan
    University of California Santa Barbara, Santa Barbara, California 93106, USA
    Nat Rev Cancer 4:253-65. 2004
  37. pmc Principles and current strategies for targeting autophagy for cancer treatment
    Ravi K Amaravadi
    Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 17:654-66. 2011
    ..Finally, we describe ongoing clinical trials involving HCQ as a first generation autophagy inhibitor, as well as strategies for the development of novel, more potent, and specific inhibitors of autophagy...
  38. ncbi Nanocarriers as an emerging platform for cancer therapy
    Dan Peer
    Department of Anesthesia, Immune Disease Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Nanotechnol 2:751-60. 2007
    ..We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment...
  39. ncbi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  40. ncbi Targeting multidrug resistance in cancer
    Gergely Szakacs
    Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Budapest Karolina Ășt 29 H 1518 Hungary
    Nat Rev Drug Discov 5:219-34. 2006
    ..We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters...
  41. ncbi Preoperative versus postoperative chemoradiotherapy for rectal cancer
    Rolf Sauer
    Department of Radiation Therapy, University of Erlangen, Erlangen, Germany
    N Engl J Med 351:1731-40. 2004
    ..In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer...
  42. ncbi Tumor cell metabolism: cancer's Achilles' heel
    Guido Kroemer
    INSERM, U848, F 94805 Villejuif, France
    Cancer Cell 13:472-82. 2008
    ..Specifically, we discuss the alterations in signal transduction pathways and/or enzymatic machineries that account for metabolic reprogramming of transformed cells...
  43. ncbi Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
  44. ncbi Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
    Giorgio Minotti
    G d Annunzio University School of Medicine, Centro Studi Sull Invecchiamento, Room 412, Via dei Vestini, 66013 Chieti, Italy
    Pharmacol Rev 56:185-229. 2004
    ..An overview of these issues confirms that anthracyclines remain "evergreen" drugs with broad clinical indications but have still an improvable therapeutic index...
  45. pmc Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor
    Jean Philippe Coppe
    Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, USA
    PLoS Biol 6:2853-68. 2008
    ..Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment...
  46. ncbi Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    James A Bonner
    University of Alabama, Birmingham, AL, USA
    Lancet Oncol 11:21-8. 2010
    ..Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival...
  47. ncbi Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Lionel Apetoh
    Institut Gustave Roussy IGR, 39 rue Camille Desmoulins, F 94805 Villejuif, France
    Nat Med 13:1050-9. 2007
    ..These results delineate a clinically relevant immunoadjuvant pathway triggered by tumor cell death...
  48. ncbi Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
    H Maeda
    Department of Microbiology, Kumamoto University School of Medicine, Honjo 2 2 1, Kumamoto, Japan
    J Control Release 65:271-84. 2000
    ..Tumor-specific vascular physiology is also described...
  49. ncbi Trastuzumab--mechanism of action and use in clinical practice
    Clifford A Hudis
    Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
    N Engl J Med 357:39-51. 2007
  50. ncbi Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Daniel J Hicklin
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
    J Clin Oncol 23:1011-27. 2005
    ....
  51. pmc Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
    Arkaitz Carracedo
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    J Clin Invest 118:3065-74. 2008
    ....
  52. ncbi MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN
    Hua Yang
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida 33612, USA
    Cancer Res 68:425-33. 2008
    ..These findings indicate that deregulation of miRNAs is a recurrent event in human ovarian cancer and that miR-214 induces cell survival and cisplatin resistance primarily through targeting the PTEN/Akt pathway...
  53. pmc Role of autophagy in cancer
    Robin Mathew
    University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA
    Nat Rev Cancer 7:961-7. 2007
    ..Recent evidence suggests that autophagy provides a protective function to limit tumour necrosis and inflammation, and to mitigate genome damage in tumour cells in response to metabolic stress...
  54. ncbi S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
    Wasaburo Koizumi
    Kitasato University School of Medicine, Sagamihara, Japan
    Lancet Oncol 9:215-21. 2008
    ....
  55. ncbi Proliferation, cell cycle and apoptosis in cancer
    G I Evan
    UCSF Cancer Center, 2340 Sutter Street, San Francisco, California 94143-0875, USA
    Nature 411:342-8. 2001
    ..Adroit targeting of these critical events should have potent and specific therapeutic consequences...
  56. ncbi Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  57. pmc The role of autophagy in cancer: therapeutic implications
    Zhineng J Yang
    Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Cancer Ther 10:1533-41. 2011
    ..The role of autophagy and its regulation in cancer cells continues to emerge, and studies aim to define optimal strategies to modulate autophagy for therapeutic advantage...
  58. ncbi Targeting RAS signalling pathways in cancer therapy
    Julian Downward
    Cancer Research UK, London Research Institute, 44 Lincoln s Inn Fields, London WC2A 3PX, UK
    Nat Rev Cancer 3:11-22. 2003
    ..Rational therapies that target the RAS pathways might inhibit tumour growth, survival and spread. Several of these new therapeutic agents are showing promise in the clinic and many more are being developed...
  59. pmc The biology of ovarian cancer: new opportunities for translation
    Robert C Bast
    Departments of Experimental Therapeutics and Systems Biology, University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, TX 77030, USA
    Nat Rev Cancer 9:415-28. 2009
    ....
  60. ncbi Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
    H Walczak
    Immunex Corporation, Seattle, Washington 98101, USA
    Nat Med 5:157-63. 1999
    ..17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection...
  61. ncbi Diagnosis of gastrointestinal stromal tumors: A consensus approach
    Christopher D M Fletcher
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston MA 02115, USA
    Hum Pathol 33:459-65. 2002
    ....
  62. pmc Targeting DNA topoisomerase II in cancer chemotherapy
    John L Nitiss
    Molecular Pharmacology Department, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Nat Rev Cancer 9:338-50. 2009
    ..These studies promise refined targeting of TOP2 as an effective anticancer strategy...
  63. pmc Molecular targeted therapies in hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 48:1312-27. 2008
    ..Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine...
  64. pmc Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
    Gerald S Falchook
    Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet 379:1893-901. 2012
    ..We aimed to assess its safety and tolerability and to establish a recommended phase 2 dose in patients with incurable solid tumours, especially those with melanoma and untreated, asymptomatic brain metastases...
  65. pmc Molecular mechanisms of resistance and toxicity associated with platinating agents
    Cara A Rabik
    Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 5841 S Maryland Avenue, Box MC2115, Section of Hem Onc, Chicago, IL 60637, United States
    Cancer Treat Rev 33:9-23. 2007
    ..Although the purpose of this review is to provide an overview of cisplatin, carboplatin, and oxaliplatin, we have focused primarily on preclinical data that has clinical relevance generated over the past five years...
  66. ncbi Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    Charles L Vogel
    University of Miami School of Medicine, Comprehensive Cancer Research Group Inc, and Columbia Cancer Research Network of Florida, Miami, FL, USA
    J Clin Oncol 20:719-26. 2002
    ..To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer...
  67. pmc Development of a second-generation antiandrogen for treatment of advanced prostate cancer
    Chris Tran
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 324:787-90. 2009
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  68. ncbi The NCI60 human tumour cell line anticancer drug screen
    Robert H Shoemaker
    Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702 1201, USA
    Nat Rev Cancer 6:813-23. 2006
    ..Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy...
  69. pmc A distinct "side population" of cells with high drug efflux capacity in human tumor cells
    C Hirschmann-Jax
    Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, and DeBakey Department of Surgery, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 101:14228-33. 2004
    ....
  70. pmc Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
    Nikhil Wagle
    Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D1542, Boston, MA, USA
    J Clin Oncol 29:3085-96. 2011
    ..These results provide an instructive framework for assessing mechanisms of acquired resistance to kinase inhibition and illustrate the use of emerging technologies in a manner that may accelerate personalized cancer medicine...
  71. ncbi Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients
    Jean Pierre Pignon
    Department of Biostatistics and Epidemiology, Institut Gustave Roussy, Villejuif, France
    Radiother Oncol 92:4-14. 2009
    ..However the heterogeneity of the results limited the conclusions and prompted us to confirm the results on a more complete database by adding the randomised trials conducted between 1994 and 2000...
  72. ncbi Awakening guardian angels: drugging the p53 pathway
    Christopher J Brown
    p53 Laboratory A STAR, 8A Biomedical Grove, Immunos, Singapore 138648
    Nat Rev Cancer 9:862-73. 2009
    ....
  73. ncbi Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
    ..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab...
  74. pmc Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment
    Giulia Bertolini
    Molecular Cytogenetics Unit, Department of Experimental Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, 20133 Milan, Italy
    Proc Natl Acad Sci U S A 106:16281-6. 2009
    ..The molecular features of these cells may provide the rationale for more specific therapeutic targeting and the definition of predictive factors in clinical management of this lethal disease...
  75. pmc Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
    Sonja J Heidorn
    The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK
    Cell 140:209-21. 2010
    ....
  76. ncbi Drug penetration in solid tumours
    Andrew I Minchinton
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada
    Nat Rev Cancer 6:583-92. 2006
    ....
  77. pmc Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
    Joan T Garrett
    Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
    Oncotarget 2:1314-21. 2011
    ..Thus, combination therapies that target RTKs, PI3K, and mTOR activities may be required to maximize the clinical benefit derived from treatment with these inhibitors...
  78. ncbi Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
    Sauveur Michel Maira
    Oncology Disease Area, Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland
    Mol Cancer Ther 7:1851-63. 2008
    ..Collectively, the preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties. NVP-BEZ235 is currently in phase I clinical trials...
  79. ncbi Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
    Nick Thatcher
    Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK
    Lancet 366:1527-37. 2005
    ..This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer...
  80. ncbi A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    J Clin Oncol 27:672-80. 2009
    ..This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC...
  81. ncbi Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    Federico Cappuzzo
    Department of Medical Oncology, Ospedale Civile di Livorno, Livorno, Italy
    Lancet Oncol 11:521-9. 2010
    ....
  82. pmc PARP inhibition: PARP1 and beyond
    Michele Rouleau
    Laval University Medical Research Center, Laval University, Quebec, Canada
    Nat Rev Cancer 10:293-301. 2010
    ....
  83. pmc Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened
    James K Chen
    Department of Molecular Biology and Genetics, Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Genes Dev 16:2743-8. 2002
    ..These observations reveal the mechanism of cyclopamine's teratogenic and antitumor activities and further suggest a role for small molecules in the physiological regulation of Smo...
  84. ncbi Histone deacetylase inhibitors: molecular mechanisms of action
    W S Xu
    Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Oncogene 26:5541-52. 2007
    ..The plurality of mechanisms of HDACi-induced cell death reflects both the multiple substrates of HDACs and the heterogeneous patterns of molecular alterations present in different cancer cells...
  85. ncbi Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer
    Pierre Laurent-Puig
    INSERM UMR S775 Molecular Basis of Xenobiotics Response, Paris, France
    J Clin Oncol 27:5924-30. 2009
    ..However, only half of these patients will benefit from treatment, suggesting the need to identify additional biomarkers for cetuximab-based treatment efficacy...
  86. ncbi Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  87. ncbi ErbB receptors and signaling pathways in cancer
    Nancy E Hynes
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Curr Opin Cell Biol 21:177-84. 2009
    ..Finally, mechanisms contributing to resistance to ErbB-targeted therapeutics will also be discussed...
  88. ncbi Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    Andrew Tutt
    Breakthrough Breast Cancer Research Unit, Guy s Hospital Campus, King s College London School of Medicine, London, UK
    Lancet 376:235-44. 2010
    ..We therefore assessed the efficacy, safety, and tolerability of olaparib alone in women with BRCA1 or BRCA2 mutations and advanced breast cancer...
  89. pmc Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer
    Daniel P Silver
    Dana Farber Cancer Institute, Department of Medical Oncology, Smith 209, 1 Jimmy Fund Way, Boston, MA 02115, USA
    J Clin Oncol 28:1145-53. 2010
    ..CONCLUSION Single-agent cisplatin induced response in a subset of patients with TNBC. Decreased BRCA1 expression may identify subsets of TNBCs that are cisplatin sensitive. Other biomarkers show promise in predicting cisplatin response...
  90. ncbi The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007
    ..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes...
  91. ncbi A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Katrien Berns
    Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Cancer Cell 12:395-402. 2007
    ..Thus, assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy...
  92. ncbi Topoisomerase I inhibitors: camptothecins and beyond
    Yves Pommier
    Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, 20892 4255, USA
    Nat Rev Cancer 6:789-802. 2006
    ....
  93. ncbi PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    Yoichi Nagata
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 6:117-27. 2004
    ..Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance...
  94. ncbi Cancer nanotechnology: opportunities and challenges
    Mauro Ferrari
    Division of Haematology and Oncology, 110U Davis Heart and Lung Research Institute, The Ohio State University, 473 West 12th Avenue, Columbus OH 43210 1002, USA
    Nat Rev Cancer 5:161-71. 2005
    ..These and other nanodevices can provide essential breakthroughs in the fight against cancer...
  95. ncbi Somatic activation of KIT in distinct subtypes of melanoma
    John A Curtin
    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143 0808, USA
    J Clin Oncol 24:4340-6. 2006
    ..This raises the question of whether other aberrations are occurring in the MAP kinase cascade in the melanoma types with infrequent mutations of BRAF and NRAS...
  96. pmc The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
    Alberto M Martelli
    Department of Human Anatomical Sciences University of Bologna, Bologna, Italy
    Oncotarget 1:89-103. 2010
    ..Efforts to exploit pharmacological inhibitors of the PI3K/Akt/mTOR cascade which show efficacy and safety in the clinical setting are now underway...
  97. ncbi Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
    Francois Xavier Mahon
    Laboratoire d HĂ©matologie et Service des Maladies du Sang, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
    Lancet Oncol 11:1029-35. 2010
    ..We aimed to assess whether imatinib can be discontinued without occurrence of molecular relapse in patients in complete molecular remission (CMR) while on imatinib...
  98. ncbi NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    Violeta Serra
    Laboratory of Oncology Research, Medical Oncology Service, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer Res 68:8022-30. 2008
    ..In summary, NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha...
  99. ncbi Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
    Neil P Shah
    Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Cancer Cell 2:117-25. 2002
    ..Multiple independent mutant clones were detected in a subset of relapsed cases. Our data support a clonal selection model of preexisting BCR-ABL mutations that confer imatinib resistance...
  100. ncbi Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Martine J Piccart-Gebhart
    Medicine Department, Jules Bordet Institute, Blvd de Waterloo 125, 1000 Brussels, Belgium
    N Engl J Med 353:1659-72. 2005
    ..We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy...
  101. ncbi Targeting cancer with small molecule kinase inhibitors
    Jianming Zhang
    Dana Farber Cancer Institute, Department of Cancer Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 9:28-39. 2009
    ..This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors...

Research Grants63

  1. International Training and Research in Environmental and Occupational Health
    NELSON K STEENLAND; Fiscal Year: 2012
    ..We also plan on research regarding the effect of interventions. ..
  2. Targeting Adipocyte Lipases to Treat Pancreatic Cancer-Associated Cachexia
    Enrique Saez; Fiscal Year: 2013
    ..that address the adipocyte dysfunction that is the basis of the cachexia, in combination with standard antineoplastic agents, may dramatically enhance their quality of life and the chances of success of the anti-tumor treatment...
  3. c-Src/EGF Receptors Interactions and Therapeutic Resistance in Breast Cancer
    Sarah J Parsons; Fiscal Year: 2010
    ..Our studies aim to achieve a better understanding of which cancers demonstrate pY845-dependent resistance to therapy, so that we can target this pathway for intervention. ..
  4. Microtubule dependent AR signaling predicts taxane sensitivity
    Paraskevi Giannakakou; Fiscal Year: 2013
    ..Given that the taxanes have recently emerged as the first class of antineoplastic agents to improve survival for metastatic CRPC, currently representing the standard of care for first-line ..
  5. Characterization of a GPCR-blocking antibody for the treatment of breast cancer.
    GARRET GUENTHER; Fiscal Year: 2011
    ..Completion of the proposed project will determine if this new drug is likely to be effective in treating breast tumors. ..
  6. Increasing efficacy of antineoplastic drugs with gap junction enhancers
    Thu Annelise Nguyen; Fiscal Year: 2010
    ..Our goal is to increase efficacy of the current antineoplastic drugs via increasing of cell communication by a novel gap junction enhancer. ..
  7. Phase I Clinical Trials of Anti-Cancer Agents
    Mark J Ratain; Fiscal Year: 2013
    ..applicant): This competing renewal proposes to define the recommended phase II dose and toxicities of new antineoplastic agents, including approaches to amelioration of such toxicity;to define the pharmacokinetics, pharmacodynamics, ..
  8. The Role of SNCG in the Carcinogenesis of Uterine Papillary Serous Carcinoma
    Barbara M Buttin; Fiscal Year: 2010
    ..has potential as a biomarker for aggressive behavior in UPSC and may be able to help direct the choices of antineoplastic agents used to treat it...
  9. Phase I Molecular and Clincal Pharmacodynamic Trials
    Edward M Newman; Fiscal Year: 2013
    ..effective Phase II dose, and to an understanding of the spectrum of normal tissue toxicity for specific antineoplastic agents that are directed against novel molecular pathways, but will also provide a mechanistic validation of the ..
  10. COMBINATORIAL APPROACHES FOR NOVEL ANTICANCER AGENTS
    JOHN LAZO; Fiscal Year: 2009
    ..Our overall hypothesis is that novel;structurally unique, lead antineoplastic agents can be generated and identified by an integrated use of contemporary combinatorial chemistry, biochemistry,..
  11. Dual drug high dose PLGA-lipid hybrid nanoparticles for drug delivery
    Sergio Sandoval; Fiscal Year: 2011
    ..through the alteration in the drug efflux proteins responsible for the removal of many commonly used antineoplastic agents. One possible way to overcome this drug efflux pump is to give higher doses of chemotherapy...
  12. Pharmacogenomics of a Cytidine Analogue, Gemcitabine
    Liewei Wang; Fiscal Year: 2010
    ..Therefore, the proposed studies will provide an ideal "Transition Career Development" path to extend her pharmacogenomic studies of antineoplastic drugs and to make it possible for her to submit a future R01 Cancer Research grant. ..
  13. Mnk Pathways and IFN-responses in Malignant Cells
    Leonidas C Platanias; Fiscal Year: 2013
    ..of IFN-dependent antileukemic responses;provide important information on the events that lead to malignant cell resistance;and form the basis for the development of novel antineoplastic agents and approaches to overcome such resistance.
  14. Water Soluble Antimitotics That Circumvent Rumor Resistance
    Susan L Mooberry; Fiscal Year: 2013
    ....
  15. Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
    Edward Chu; Fiscal Year: 2013
    ..is the strategy that will be pursued with the following objectives to : define the toxicities of new antineoplastic agents in patients with advanced cancer;re-define (as necessary)the toxicities and PK of existing anticancer ..
  16. Selection and Characterization of PSMA Ligands from Phage-Displayed Libraries
    Gary Fujii; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  17. Chemical Modulation of Orphan Nuclear Receptor Function
    Sridhar Mani; Fiscal Year: 2013
    ..It is also hoped that these antagonists will enhance the activity, and minimize the toxicity, of select antineoplastic agents (e.g., tamoxifen, paclitaxel are PXR agonist at concentrations observed at steady-state in humans)...
  18. ANTINEOPLASTIC AGENTS FROM MARINE ORGANISMS
    Chris M Ireland; Fiscal Year: 2010
    ..by applicant): This is a revised application requested continuation of grant RO1 CA 36622 entitled "Antineoplastic Agents from Marine Organisms." The funding requested is for years 24-28 of the program...
  19. MODULATION OF MULTIDRUG RESISTANCE BY CYCLOSPORIN A
    Charles Erlichman; Fiscal Year: 1992
    ..The proposed studies will evaluate the importance of P-glycoprotein in clinical resistance to MDR and determine whether cyclosporin A can reverse the MDR phenotype in patients...
  20. Fatty Acid Synthase Inhibitors: Ovarian Cancer Therapy
    ALBERT OWENS; Fiscal Year: 2007
    ..FASgen, Inc. is developing a novel set of antineoplastic agents, inhibitors of the enzyme fatty acid synthase (FAS), which is overproduced in 50-80% of ovarian cancers...
  21. Cell cycle specific CDK inhibitors as potential anti-tumor therapeutics through R
    Campbell McInnes; Fiscal Year: 2012
    ..of available drug targets will provide significant new options for the development of more effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development...
  22. Drug Delivery Systems Based on Cleavable Oxanorbornadienes
    ALEXANDER KISLUKHIN; Fiscal Year: 2012
    ..Ultimately, the incorporation of these state- of-the art cancer therapies into clinical practice is sought. ..
  23. Mechanisms of Action of Anti-Mitotic Drugs
    Mary Jordan; Fiscal Year: 2007
    ..The results will elucidate mechanisms and predict possible clinical efficacy of combination therapies directed at modulating mitotic microtubule regulatory proteins in combination with taxanes and Vinca alkaloids. ..
  24. DRUG SEQUENCING RESISTANCE IN MULTIPLE MYELOMA
    Daniel Sullivan; Fiscal Year: 1999
    ..The major reason that patients fail to respond to antineoplastic agents is because of intrinsic or acquired drug resistance...
  25. Antitumor Antimitotics That Reverse Tumor Resistance
    Aleem Gangjee; Fiscal Year: 2010
    ..The study will also further define the mechanism of action of the novel series and could afford agents for clinical use. ..
  26. Synthesis of Polyketides and Terpenes
    David A Evans; Fiscal Year: 2010
    ..and the application of this methodology to the asymmetric synthesis of complex polyketide antibiotics and antineoplastic agents. The synthesis targets will include amphinidinol 3, aflastatin 3, (+) peloruside A, salvinorin A, phorbol, ..
  27. LUNG TOXIC INTERACTIONS INVOLVING THERAPEUTIC DRUGS
    JAMES KEHRER; Fiscal Year: 1991
    ..The results of these studies will reveal any differences in these parameters that are related to the species treated or the damaging agents employed...
  28. Enhanced Drug Delivery to Metastatic Brain Tumors
    Keith Black; Fiscal Year: 2006
    ..While adequate delivery of drugs occurs to systemic tumors, the BTB limits delivery of antineoplastic agents to metastatic brain tumors...
  29. HYDROXYUREA SYNERGY WITH OTHER ANTICANCER DRUGS IN VIVO
    William Vaughan; Fiscal Year: 1990
    ....
  30. ANTINEOPLASTIC DRUG HEPATIC INTERACTIONS
    Dean Brenner; Fiscal Year: 1990
    ..2) Compounds which inhibit or induce hepatic drug metabolizing enzymes will pertrub the metabolism of antineoplastic agents in a manner different from those that occur when liver cells are killed or the liver parenchyma is ..
  31. LEUKOCYTE ACTIVATION--INFLUENCE OF THE CYTOSKELETON
    Marilyn Pike; Fiscal Year: 1993
    ..regulation of normal leukocyte activation and differentiation will allow the development of more specific antineoplastic agents for the treatment of leukemias and lymphomas and may result in new therapies for augmentation of the ..
  32. PEPTIDOMIMETIC DRUGS--SUBSTRATES FOR PEPTIDE TRANSPORTER
    Malliga Ganapathy; Fiscal Year: 2000
    ..Examples of these peptidomimetic drugs include several antibacterial, antiviral, antihypertensive, and antineoplastic agents. The efficiency with which these drugs are absorbed in the gastrointestinal tract after oral ..
  33. Molecular Target Focused Discovery of Anticancer Drugs
    George R Pettit; Fiscal Year: 2010
    ....
  34. Thermally Targeted Delivery of DOX
    RAYMOND BUDDE; Fiscal Year: 2007
    ..by inherent tumor resistance to radiation or chemotherapy and by toxicity from systemic administration of antineoplastic agents. Our long-term goal is to overcome these limitations by developing for localized tumors a targeted ..
  35. Molecular Target Focused Discovery of Anticancer Drugs
    GEORGE PETTIT; Fiscal Year: 2007
    ..In summary, the proposed research will be sharply aimed at the discovery and very rapid development of new anticancer drugs for the NCI programs direct at improving human cancer treatments. ..
  36. DNA TOPOISOMERASE ACTIVITY AND CANCER THERAPY
    Daniel Sullivan; Fiscal Year: 1992
    Numerous antineoplastic agents, including intercalators and epipodophyllotoxins, exert their cytotoxic effect via inhibition of the nuclear enzyme, DNA topoisomerase II...
  37. Translational Apparatus as a Target for Drug Discovery
    Vitaly Polunovsky; Fiscal Year: 2004
    ..To achieve these aims, we have assembled an experienced investigative team committed to anticancer drug discovery . ..
  38. Side-by-side comparison of blood-brain barrier models
    Edward Rapp; Fiscal Year: 2006
    ..As such, it will be perfectly suited for extensive pharmacological and physiological studies and will accelerate the process leading to new and more effective drug therapies aimed at CNS diseases. [unreadable] [unreadable] [unreadable]..
  39. DEVELOPMENT OF DRUG DELIVERY SYSTEMS BASED ON NEW BIO-S*
    Ian McLennan; Fiscal Year: 2002
    ..The in vivo drug delivery systems can, in principal, ameliorate the harmful side effect of antineoplastic agents. Over the past 4 years, ECOSYNTHETIX has developed a series of biobased products including new sugar based ..
  40. TOPOISOMERASE I STRUCTURE AND REGULATION
    Eric Rubin; Fiscal Year: 1999
    ..Additional studies will attempt to identify other binding proteins and to investigate the effects of these proteins on topoisomerase I function and on the interaction between topoisomerase I and inhibitors such as camptothecin. ..
  41. Topoisomerase II-directed drugs and cell death
    John Robertson; Fiscal Year: 2006
    ..poisons, which cause double-stranded DNA breaks and are among the most effective and widely prescribed antineoplastic agents, lead to the engagement of the mitochondrial (intrinsic) apoptotic pathway...
  42. PHARMACOGENTIC ASPECTS OF ANTINEOPLASTIC DRUG METABOLISM
    Kenneth Hande; Fiscal Year: 1991
    ..The goal of our laboratory is to determine if the rate of metabolism of some antineoplastic agents might be genetically controlled...
  43. TUMOR CELL LINE PROLIFERATION, MOTILITY AND INVASIVENESS
    DAVID RIESE; Fiscal Year: 2000
    ..Molecules that inhibit EGFR expression or activity are being assessed as potential antineoplastic agents. One specific aim of this study is to identify which set of putative EGFR tyrosine kinase inhibitors has ..
  44. Development of liposomal fenretinide and safingol
    William Ernst; Fiscal Year: 2004
    ..Safingol has been shown to synergize with antineoplastic agents (i.e...
  45. HEALTH AND OCCUPATIONAL EXPOSURE TO ANTI-CANCER DRUGS
    Barbara Valanis; Fiscal Year: 1993
    ....
  46. PHARMACOLOGICAL EFFECTS OF ETHER LIPID ANALOGS
    EDWARD MODEST; Fiscal Year: 1991
    ..to continue and expand our studies on new ether lipid (EL) analogs of platelet activating factor as antineoplastic agents. These compounds inhibit malignant cells in three ways: by direct cytotoxic or cytostatic action, by ..
  47. SYNTHESIS OF AMINO ACID-DERIVED NATURAL PRODUCTS
    David Evans; Fiscal Year: 2000
    ..the development of new stereoselective reactions which are relevant to the synthesis of antibiotic and antineoplastic agents derived from amino acid constituents The methodological studies dealing with new reaction discovery will ..
  48. PHOSPHONIUM-TAXOL CONJUGATES AS ANTITUMOR DRUGS
    Xiaoen Wang; Fiscal Year: 1993
    ..Phosphonium salts are antineoplastic agents that are selectively concentrated in many carcinoma cells relative to untransformed cells and have ..
  49. Targeted Delivery of c-Myc Inhibitory Polypeptides
    Drazen Raucher; Fiscal Year: 2007
    ..by inherent tumor resistance to radiation or chemotherapy and toxicity from systemic administration of antineoplastic agents. Our long term goal is to overcome these limitations by developing a targeted therapeutic approach for ..
  50. PLANT ANTITUMOR AGENTS: ISOLATION AND IDENTIFICATION
    Norman Farnsworth; Fiscal Year: 1991
    ..by) naturally occuring substances has also largely contributed to the clinical success demonstrated by antineoplastic agents produced synthetically...
  51. DRUG RESISTANCE AND GENE AMPLIFICATION IN EUKARYOTES
    Geoffrey Wahl; Fiscal Year: 1992
    ..ample documentation in human tumors in vivo that gene amplification can lead to resistance to a variety of antineoplastic agents alone, or in combination...
  52. TYROSINE KINASE INHIBITORS AS ANTINEOPLASTIC AGENTS
    Brian Druker; Fiscal Year: 2001
    ..This information would be useful for the design of more potent and specific ABL kinase inhibitors and would be helpful in the design of inhibitors of other tyrosine kinases. ..
  53. NMR DETECTION OF 13C-TEMOZOLOMIDE IN CANINE BRAIN TUMORS
    Anthony Mancuso; Fiscal Year: 2001
    ..proposed study employs temozolomide as a prototype to test the general concept of using 13C-labeling of antineoplastic agents as a method for monitoring their pharmacokinetics by NMR spectroscopy...
  54. TAILORING ANTICANCER THERAPY TO LOSS OF P53
    David Fisher; Fiscal Year: 2003
    ..abstract_text> ..
  55. Flavopiridol as a Potential Therapy in Multiple Myeloma
    Keith Bible; Fiscal Year: 2005
    ..clinical trials, 1) binds to DNA with a dissociation constant similar to that of other DNA-directed antineoplastic agents, 2) disrupts STAT-3/DNA interactions in vitro in three model systems, and 3) down regulates antiapoptotic ..
  56. TOPOISOMERASE II EXPRESSION IN DRUG RESISTANCE
    Shu wing Ng; Fiscal Year: 2001
    ..is an essential enzyme and is also the intracellular target for the number of clinically most effective antineoplastic agents. The intracellular level of top II is an import determining factor for the cellular sensitivity to top II-..
  57. MABZYMES TO ACTIVATE ANTICANCER GLUCURONIDE PRODRUGS
    JAMES LARRICK; Fiscal Year: 1993
    ..To increase specificity of drug delivery antineoplastic agents have been linked to monoclonal antibodies (MABs) that bind to antigens selectively expressed on tumor ..
  58. THE ACTION OF ARA-C AND 5-AZA-C ON MEMBRANE SYNTHESIS
    CAROLE JELSEMA; Fiscal Year: 1980
    ..The goal of this investigation is to further delineate the mode of action of these antineoplastic agents. Current mechanisms for the cytotoxic action of these cytosine analogs implicate the phosphorylated ..
  59. SYNTHESIS OF THE ANTITUMOR MACROLIDE SPONGISTATIN 1
    ANATOLY PINCHUK; Fiscal Year: 2001
    ..As a result of this training, the candidate will obtain a high level of expertise in the natural products synthesis that will allow him to start an independent research career in an academic environment. ..
  60. TRAINING IN PHARMACOLOGY OF ANTINEOPLASTIC AGENTS
    SUE ECKHARDT; Fiscal Year: 2009
    ..Program sponsor an interdisciplinary postdoctoral training program in the "Clinical Pharmacology of Antineoplastic Agents." The goal of this training program is to provide individuals with the complex skills necessary to develop ..
  61. Thermally Targeted Delivery of Therapeutic Peptides
    Drazen Raucher; Fiscal Year: 2009
    ..inherent tumor resistance to radiation or chemotherapy, and toxicity from systemic administration of antineoplastic agents. The result is a narrow therapeutic index for most current chemotherapeutic agents...
  62. Rb, p53, & Bcl-2 Proteins in Apoptosis
    STEVEN WEINTRAUB; Fiscal Year: 2007
    unreadable] DESCRIPTION (provided by applicant): The therapeutic value of DNA-damaging antineoplastic agents is dependent upon their ability to induce tumor cell apoptosis while sparing most normal tissues...
  63. ANTICANCER DRUG EFFLUX TRANSPORTERS IN DEVELOPMENT
    Alan Sartorelli; Fiscal Year: 2005
    ..upon malignant cells the ability to withstand exposure to lethal doses of many structurally unrelated antineoplastic agents. Multidrug resistance has been characterized by the overexpression of membrane-associated glycoproteins; ..